Oppenheimer & CO Inc Capricor Therapeutics, Inc. Transaction History
Oppenheimer & CO Inc
- $6.42 Billion
- Q3 2024
A detailed history of Oppenheimer & CO Inc transactions in Capricor Therapeutics, Inc. stock. As of the latest transaction made, Oppenheimer & CO Inc holds 68,408 shares of CAPR stock, worth $898,197. This represents 0.02% of its overall portfolio holdings.
Number of Shares
68,408
Previous 54,646
25.18%
Holding current value
$898,197
Previous $260,000
300.0%
% of portfolio
0.02%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding CAPR
# of Institutions
92Shares Held
8.13MCall Options Held
1.78MPut Options Held
1.4M-
Black Rock Inc. New York, NY1.63MShares$21.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.58MShares$20.7 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA638KShares$8.38 Million0.0% of portfolio
-
State Street Corp Boston, MA512KShares$6.73 Million0.0% of portfolio
-
Superstring Capital Management LP New York, NY337KShares$4.43 Million4.49% of portfolio
About CAPRICOR THERAPEUTICS, INC.
- Ticker CAPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,346,200
- Market Cap $320M
- Description
- Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for th...